Sichuan Kelun Pharmaceutical (002422.SZ): Amara has cumulatively increased its shareholding by 0.2%.

Gelonghui, March 27, Sichuan Kelun Pharmaceutical (002422.SZ) announced that as of the date of this announcement, shareholders holding more than 5% of the shares, Yaan State-owned Assets Company, has cumulatively increased its shareholding in the company by 3,182,100 shares through the centralized bidding trading system of the Shenzhen Stock Exchange. The shares acquired account for 0.20% of the company's total share capital (considering the share repurchase cancellation during this period, see the company’s "Announcement on the Completion of Some Share Buyback Cancellation and Change of Shares" (Announcement No.: 2025-017), the same below), with an increased amount of 98.9768 million yuan. This is part of Yaan State-owned Assets Company's shareholding plan.

Gelonghui FinanceMar 27 05:58 ET

While Insiders Own 27% of Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422), Individual Investors Are Its Largest Shareholders With 46% Ownership

Simply Wall StMar 26 01:17 ET

Kelun Pharma's Subsidiary Gets Nod to Trial Tumor Drug

MT NewswiresMar 25 23:57 ET

Sichuan Kelun Pharmaceutical (002422.SZ): The clinical trial application for the radiopharmaceutical conjugate drug (RDC) SKB107 has been approved.

Sichuan Kelun Pharmaceutical (002422.SZ) released an announcement, and the company recently learned that Kelun Botai will launch on March 2, 2025...

Zhitong FinanceMar 25 08:03 ET

GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.

GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.

Zhitong FinanceMar 16 21:18 ET

Goldman Sachs: gives SKB BIO-B a 'Buy' rating with a Target Price of 239.14 HKD.

Goldman Sachs released a research report stating that SKB BIO-B (06990) has been given a "Buy" rating, with a 12-month target price of HKD 239.14 calculated using risk-adjusted Cash / Money Market Discounted Cash Flow (DCF) method, assuming the following conditions: 1) a discount rate of 11%; 2) a terminal growth rate of 3%; 3) a success probability (PoS) adjusted based on the average success rates of the Industry at different stages and current clinical data. The firm believes that SKB BIO has the potential to become a significant player in the Global ADC field, focusing on developing differentiated antibody-drug conjugates (ADC) for global patients and achieving commercialization.

Sina Hong Kong StocksMar 13 23:26 ET